Actively Recruiting
Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy
Led by University of Udine · Updated on 2025-04-02
90
Participants Needed
1
Research Sites
84 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.
CONDITIONS
Official Title
Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Women of fertile age
- Clinical-ultrasound or histological diagnosis of endometriosis
- Provided informed consent
You will not qualify if you...
- Pregnancy
- Pre-menarcheal or post-menopausal status
- Chronic pelvic pain syndrome with or without central sensitization assessed by the Central Sensitization Inventory Test (CSI)
- Neoplasia, diabetes, BMI > 30 kg/m2, coagulopathies, autoimmune diseases, or other conditions affecting salivary miRNA measurement
- Currently undergoing progestin therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Udine
Udine, UD, Italy, 33100
Actively Recruiting
Research Team
M
Matilde Degano, dr
CONTACT
A
Anna Biasioli, dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here